Evidence map›Paper›PMID 14676945›Full record

ArticleDiabetologia2004

Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes.

S Cellek, W Qu, A M Schmidt, S Moncada

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Nitrergic Enteric Neurons in Health and Disease-Focus on Animal Models.International journal of molecular sciences · 2019
    Review
  10. Article
  11. Prediabetes in Colombia: Expert Consensus.Colombia medica (Cali, Colombia) · 2017
    Review
  12. Article
  13. Quercetin Isolated fromJournal of diabetes research · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

S CellekWolfson Institute for Biomedical Research, University College London, London, UK. s.cellek@ucl.ac.uk
W Qu
A M Schmidt
S Moncada
Columbia University · USUniversity College London · GBWolfson Foundation · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisWe have previously shown that in diabetes nitrergic neurones innervating the urogenital and gastrointestinal organs undergo a selective degenerative process. This comprises an initial insulin-reversible decrease in neuronal nitric oxide synthase (nNOS) in the axons, followed by apoptosis of the nitrergic neurones, a process that is not reversible by insulin. Since apoptosis was independent of serum glucose concentrations, and advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of diabetic complications, we have now measured AGEs in the serum and penis, pyloric sphincter and pelvic ganglia of diabetic animals at different times after streptozotocin treatment. Furthermore, we have studied their effect in vitro on human neuroblastoma (SH-SY5Y) cells in the presence or absence of nNOS expression.

methodsSerum AGEs were measured using fluorometry and ELISA. Accumulation of AGEs in the tissues was evaluated with immunohistochemistry. The viability, apoptosis and oxidative stress in SH-SY5Y cells were measured upon exposure to AGEs or high concentrations of glucose.

resultsAGEs increased gradually in the serum and tissues of streptozotocin-induced diabetic rats; this process was not affected by delayed insulin treatment. In SH-SY5Y cells, AGEs, but not high glucose concentrations, increased the reactive oxygen species and caspase-3-dependent apoptosis in a synergistic fashion with endogenous nitric oxide (NO). Apoptosis was prevented by treatment with a NOS inhibitor, a pan-caspase inhibitor, a soluble receptor of AGEs or an anti-oxidant, but not an inhibitor of soluble guanylate cyclase. CONCLUSIONS/

interpretationThe synergistic actions of NO and AGEs account for the irreversible nitrergic degeneration in diabetes.

Indexed as

ApoptosisAnimalsBlood GlucoseBody WeightCaspase 3Caspase InhibitorsCaspasesCell Line, TumorCholine O-AcetyltransferaseDiabetes Mellitus, ExperimentalDiabetic NeuropathiesDrug SynergismEnzyme InhibitorsEsophagogastric JunctionGangliaGene ExpressionBlood GlucoseCASP3 protein, humanCasp3 protein, ratCaspase 3Caspase InhibitorsCaspasesCholine O-AcetyltransferaseEnzyme InhibitorsGlucoseGlycation End Products, AdvancedInsulinNitric OxideNitric Oxide SynthaseNitric Oxide Synthase Type INos1 protein, ratReactive Oxygen SpeciesReceptor for Advanced Glycation End ProductsReceptors, ImmunologicSerum AlbuminTretinoin

Identifiers

PMID14676945
OpenAlexW2146655079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.